Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
- 295 Downloads
Tumor hypoxia-induced epithelial–mesenchymal transition (EMT) is critical in promoting cancer metastasis. We recently discovered a novel microtubule inhibitor, MPT0B098, that employs a novel antitumor mechanism. It destabilizes hypoxia-inducible factor (HIF)-1α mRNA by blocking the function of human antigen R. Thus, we proposed that MPT0B098 modulates hypoxia-induced EMT.
In vitro IC50 values were determined through the methylene blue dye assay. To investigate molecular events, reverse transcriptase-polymerase chain reaction, Western blotting, immunofluorescence staining, and wound healing assay were employed.
MPT0B098 significantly inhibited HIF-1α expression, epithelial-to-mesenchymal morphology changes, and migratory ability in the human head and neck squamous cell carcinoma cell line OEC-M1. Furthermore, after MPT0B098 treatment, the expression of two mesenchymal markers, vimentin and N-cadherin, was downregulated under hypoxic conditions. Moreover, MPT0B098 suppressed hypoxia-induced EMT in part by inhibiting EMT-activating transcription factors, Twist and SNAI2/Slug. In addition, the inhibition of hypoxia-induced F-actin rearrangement and focal adhesion kinase phosphorylation may have contributed to suppression of EMT by MPT0B098in OEC-M1 cells. MPT0B098 significantly inhibited transforming growth factor(TGF)-β-induced phosphorylation of receptor-associated Smad2/3 by downregulating TGF-β mRNA and protein expression.
Taken together, this study provides a novel insight into the role of MPT0B098 in inhibiting hypoxia-induced EMT, suggesting its potential use for treating head and neck cancers.
KeywordsHypoxia Epithelial to mesenchymal transition Microtubule inhibitor TGF-β Head and neck cancer
focal adhesion kinase
glyceraldehyde 3-phosphate dehydrogenase
hypoxia-induced factor 1 alpha
head and neck squamous cell carcinoma
human antigen R
transforming growth factor beta
In solid tumors, blood vessels form abnormally and are dysfunctional, resulting in an inability to supply sufficient oxygen and nutrients to the growing tumor mass . Although a decrease in oxygen tension can be lethal for some cells, many tumor cells can survive under hypoxic conditions . Tumor cells in hypoxia are resistant to radiation and chemotherapy; furthermore, hypoxic conditions can promote tumor progression and metastasis through numerous direct and indirect mechanisms . The most critical factor responding to hypoxic conditions is hypoxia-inducible factor (HIF)-1α, a basic helix–loop–helix transcription factor composed of an α subunit (regulated by the amount of oxygen tension) and β subunit (constitutively expressed) .
Epithelial–mesenchymal transition (EMT) is a cellular program in which epithelial cells lose their cell polarity and cell–cell adhesion ability and become mesenchymal cells by acquiring a fibroblastic morphology and migratory and invasive features. First recognized as a characteristic of embryogenic development, EMT is now indicated to be critical in tumor malignant transformation and metastasis . Ample evidence indicates that hypoxia leads to characteristic changes in cell morphology that induce a mesenchymal-like phenotype and facilitate tumor cell metastasis .
Chemicals and antibodies
MPT0B098 was synthesized by Prof. Jing-Ping Liou at the College of Pharmacy, Taipei Medical University, Taipei, Taiwan. The detailed synthetic procedure was described previously . Colchicine and paclitaxel were purchased from Sigma-Aldrich (St. Louis, MO). Monoclonal antibodies for Smad2, phospho-Smad2 (Ser465/467), Smad3, phospho-Smad3, Smad2/3, and SNAI2/Slug and polyclonal antibodies for transforming growth factor (TGF)-β, focal adhesion kinase (FAK), and phospho-FAK were purchased from Cell Signaling Technology (Danvers, MA). Monoclonal antibodies for HIF-1α and N-cadherin were purchased from BD Biosciences (San Jose, CA). A polyclonal antibody for vimentin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A polyclonal antibody for Twist was purchased from GeneTex (Irvine, CA). A monoclonal antibody for GAPDH was purchased from Merck Millipore (Darmstadt, Germany). All other chemicals of standard analytic grade or higher were purchased from E. Merck Co. (Darmstadt, Germany) or Sigma-Aldrich (St. Louis, MO).
Cell lines and cell culture
OEC-M1 cells, derived from a human oral epidermoid carcinoma, were established and provided by Dr. Ching-Liang Meng from the Department of Dentistry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan . The cells were cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum in a humidified 5% CO2 incubator at 37 °C. For hypoxic conditions, cells were incubated in a hypoxic chamber with a gas mixture of 1% O2 and 5% CO2 balanced with nitrogen.
Cell morphology assay
Cells were stained with 0.5% crystal violet in 95% ethanol for 1 h and then examined through light microscopy.
Cell viability assay
Cells in a logarithmic growth phase were cultured at a density of 10,000 cells per well in a 24-well plate. The cells were exposed to various concentrations of the test drug for 72 h. The methylene blue dye assay  was used to evaluate drug effect on cell growth. The IC50 values resulting from 50% inhibition of cell growth were calculated graphically, compared with control group growth.
Cells were initially seeded at a density of 4 × 105 cells in 100-mm2 dishes. Following treatment, cell pellets were collected and lysed in a buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 2 mM dithiothreitol, 2 mM Na3VO4, 0.25 mM PMSF, 10 mM NaF, 0.5% NP-40, and 20 μg/mL each of aprotinin, leupeptin, and pepstatin [proteinase inhibitors]). The supernatants were collected and the amount of protein was quantified. Equal amounts of protein from each lysate were separated by SDS-PAGE, blotted on polyvinylidenedifluoride membranes, conjugated with various specific primary antibodies, and then probed with appropriate secondary antibodies. The immunoreactive bands were detected using the enhanced chemiluminescent method and then visualized on Kodak Bio-MAX MR film.
Wound healing assay
Cells were grown to 80% confluence on culture dishes; then, a wound was created in the center of the cell monolayer with a plastic pipette tip. The migration of cells into the wound area was assessed after 4, 6, 8, and 18 h at 37 °C under normoxic (5% CO2, 21% O2) and hypoxic (5% CO2, 1% O2, balanced with N2) conditions. The area of denuded surface was quantified immediately and at the time points of 4, 6, 8 h after wounding. The extent of wound closure was determined by calculating the ratio between the surface area of the wound for each time point and the surface of the initial wound.
Immunofluorescence analysis of F-actin
OEC-M1 cells were fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA), permeabilized with 0.5% Triton X-100 in phosphate-buffered saline, treated with 0.1% sodium borohydride (Sigma-Aldrich, St. Louis, MO), blocked with 5% horse serum, and then incubated with phalloidin (Life Technologies, Gaithersburg, MD) for 30 min at room temperature in the dark. Nuclei were stained with DAPI. Cells were observed with an OLYMPUS fluorescence microscope.
Reverse transcriptase-polymerase chain reaction analysis
Ten micrograms of total RNA, extracted with Trizol reagent (Life Technologies, Gaithersburg, MD), were treated with DNase and converted to cDNA using the SuperScript II RNase H Reverse Transcriptase System (Invitrogen, Carlsbad, CA). Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using a Perkin-Elmer GeneAmp PCR System 2400 (Applied Biosystems, Foster City, CA). PCR primers and TaqMan probes (5′-GACCTGGA-3′) used to amplify the indicated genes were designed using Primer Express (version 1.0; Applied Biosystems) as follows: TGF-β1 forward 5′-cggagttgtgcggcagtggttga-3′ and reverse 5′-ggcgcccgggttatgctggttgta-3′ and TGF-β2 forward 5′-gtcttggatgcggcctattgc-3′ and reverse 5′-gctgcatttgcaagactttac-3′. The reaction mixture was preheated at 95 °C for 5 min, followed by 30 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 40 s; final extension was at 72 °C for 7 min. In a separate reaction, GAPDH was amplified as the reference gene. PCR products of the target genes were analyzed through electrophoresis on 2% agarose gel and visualized using ethidium bromide staining under UV light. Quantitative data was collected by measuring the bands using ImageJ (Bethesda, MD).
Quantitative data were reported as mean ± SD. Statistical calculations were completed on Microsoft Excel. P values for determining statistical significance were calculated using an unpaired two-tailed Student’s t test.
MPT0B098 exhibits low-level resistance toward OEC-M1 cell growth under hypoxic conditions
We used the methylene blue dye assay to examine the antiproliferative efficacy of MPT0B098 and other clinically used microtubule inhibitors, such as colchicine and paclitaxel, in OEC-M1 cells. As shown in Fig. 1b, MPT0B098 inhibited the growth of OEC-M1 cells with IC50 of 222 and 265 nM under normoxic and hypoxic conditions, respectively. This result indicates that hypoxia leads to increased low-level drug resistance of MPT0B098 in OEC-M1 cells (Fig. 1c).
In addition, compared with MPT0B098, other microtubule inhibitors, including colchicine and paclitaxel, exhibited higher resistance in OEC-M1 cells under hypoxic conditions than under normoxic conditions. The IC50 values of colchicine were 23 and 37 nM under normoxia and hypoxia, respectively, and the IC50 values of paclitaxel were 4.4 and 5.9 nM, respectively (Fig. 1b). These results indicate that MPT0B098 is more effective in overcoming hypoxia-induced drug resistance than colchicine and paclitaxel in OEC-M1 cells.
MPT0B098 inhibits hypoxia-induced EMT in OEC-M1 cells
On further examining the role of MPT0B098 in hypoxia-induced EMT in OEC-M1 cells, we found that OEC-M1 cells displayed epithelial characteristics under normoxic conditions, with a round morphology and linked cells (Fig. 2c, left panel). However, under hypoxic conditions, cells displayed a fibroblastic morphology and lost their cell–cell contact, which is a mesenchymal characteristic, implying that hypoxia can trigger EMT (Fig. 2c, middle panel). Notably, the transformation from epithelial to mesenchymal cell type under hypoxic conditions could be inhibited by treating cells with MPT0B098 (Fig. 2c, right panel). These results suggest that MPT0B098 may play a role in modulating hypoxia-induced EMT in OEC-M1 cells.
MPT0B098 is more potent in inhibiting hypoxia-induced mesenchymal marker expression than clinically used microtubule inhibitors
MPT0B098 suppresses hypoxia-induced EMT partially by inhibiting the expression of EMT-activating transcription factors Twist and SNAI2/slug
MPT0B098 significantly inhibits hypoxia-induced F-actin rearrangement and FAK phosphorylation
FAK is a cytoplasmic tyrosine kinase, with critical roles in the regulation of cell spreading, migration, and survival and in the downstream signaling cascade associated with its own phosphorylation [19, 20]. Changes in the organization of the actin cytoskeleton, influenced by FAK, leads to remarkable changes in the tyrosine phosphorylation of several signaling proteins localized at the focal adhesion complex . To further explore the molecular mechanisms responsible for MPT0B098 inhibition of hypoxia-induced actin cytoskeletal rearrangement, we examined the expression and activation of FAK protein. As shown in Fig. 5b and c, FAK expression and activation were increased under hypoxic conditions. Hypoxia-induced phosphorylation of FAK decreased when the hypoxic cells were treated with MPT0B098. Taken together, these results suggest that MPT0B098-inhibited FAK/actin cytoskeletal rearrangement partially contributes to EMT suppression.
MPT0B098 downregulates TGF-β-induced phosphorylation of receptor-associated Smads
To further examine the involvement of TGF-β in the hypoxia-induced activation of Smad signaling, TGF-β was applied to MPT0B098-treated hypoxic cells. TGF-β treatment significantly enhanced Smad2 and Smad3 phosphorylation even under hypoxic conditions (Fig. 6c and d). Coadministration of TGF-β and MPT0B098 significantly suppressed Smad2 and Smad3 phosphorylation in a concentration-dependent manner. In addition, MPT0B098 slightly inhibited Smad2 and Smad3 protein expression (Fig. 6c and d), suggesting that MPT0B098 influenced Smad inactivation under hypoxic conditions through TGF-β modulation.
MPT0B098 downregulates TGF-β signaling by decreasing expression levels of TGF-β mRNA and protein
MPT0B098 inhibits hypoxia-induced cell migration in OEC-M1 cells
Microtubule-targeting drugs, such as taxotere, epothilone B, discodermolide, vincristine, 2-methoxyestradiol, and colchicine, can downregulate the expression of HIF-1α protein but not HIF-1α mRNA . MPT0B098, a novel indoline-sulfonamide-based microtubule inhibitor, can destabilize HIF-1α mRNA in hypoxia by inhibiting the translocation of HuR from the nucleus to cytoplasm . This ability distinguishes MPT0B098 from other microtubule inhibitors. MPT0B098 is effective against a panel of human cancer cell lines, regardless of the p-gp170/MDR status [10, 11, 12]. Because MPT0B098 has a unique ability to modulate HIF-1α, we proposed that MPT0B098 also suppresses hypoxia-induced malignant transformation.
Hypoxia can induce EMT and enhance the migration and invasion ability of tumor cells . EMT is a key step for tumor metastasis. Hypoxia leads to characteristic changes in cell morphology, causing a mesenchymal-like phenotype, a distinct characteristic of the EMT process . In this study, we selected a highly invasive human HNSCC cell line, OEC-M1 , to clarify the role of MPT0B098 in EMT regulation. We observed that MPT0B098 could inhibit expression of HIF-1α protein and the hypoxia-induced mesenchymal-like phenotype in OEC-M1 cells (Fig. 2c). In addition, this compound was more effective, as indicated by low hypoxia-induced drug resistance, than colchicine and paclitaxel in inhibitingOEC-M1 cell growth under hypoxic conditions (Fig. 1c). As determined by expression of the two mesenchymal markers vimentin and N-cadherin, we noted that MPT0B098 was more potent in inhibiting hypoxia-induced vimentin and N-cadherin upregulation than colchicine and paclitaxel in OEC-M1 cells (Fig. 3). These results suggest that MPT0B098 is distinct from other clinically used microtubule inhibitors in its inhibition of hypoxia-induced EMT. Unlike the classic reversal of the EMT phenomenon, E-cadherin protein was slightly suppressed by MPT0B098 (Fig. 3a and 3b). Cadherins have been reported to regulate the organization and dynamics of microtubules. This behavior may also affect cadherin biology through microtubule-based vesicular traffic . Thus, the interplay between E-cadherin and microtubules may be disrupted by the inhibition of microtubule polymerization under MPT0B098 treatment. The underlying mechanisms merit further investigation.
Molecular reprogramming occurring during EMT is triggered and orchestrated by various EMT-activating transcription factors, including Twist and SNAI2/Slug . Yang et al. found that HIF-1α regulated the expression of Twist by binding directly to the hypoxia-response element in the Twist proximal promoter. In addition, silencing of Twist in HIF-1α-overexpressing or hypoxic cells reversed EMT and metastatic phenotypes . Cheng et al. reported that treatment with HIF-1α siRNA diminished the upregulation of SNAI2/Slug expression . Because MPT0B098 is effective in suppressing HIF-1α expression, we investigated the effect of MPT0B098 on modulation of Twist and SNAI2/Slug and found that the expression levels of hypoxia-induced Twist and SNAI2/Slug were significantly decreased in a concentration-dependent manner when cells were treated with various concentrations of MPT0B098 (Fig. 4).
Transcription program switching in EMT is induced by signaling pathways mediated by TGF-β, bone morphogenetic protein, Wnt-β-catenin, Notch, Hedgehog, and receptor tyrosine kinases. These pathways are activated by various dynamic stimuli from the local microenvironment. Of note, TGF-β signaling has a dominant role in EMT [22, 30, 31, 32]. Here, we demonstrated that MPT0B098 inhibits hypoxia-induced EMT by downregulating the expression levels of TGF-β mRNA (Fig. 7a) and protein (Fig. 7b). We previously demonstrated that MPT0B098 inhibited HuR translocation to the cytoplasm . HuR, an mRNA-stabilizing protein, shuttles between the nucleus and cytoplasm through several export pathways. Mobilizing HuR from the nucleus to the cytoplasm leads to maintenance of the stability of HuR-mediated target mRNAs. Increased stability of TGF-β mRNA by HuR promotes EMT in pancreatic cancer ; therefore, whether MPT0B098 affect the stability of TGF-β mRNA through HuR dependent or independent mechanisms which needs to be further investigated.
Taken together, we demonstrated for the first time that the novel microtubule Inhibitor MPT0B098 inhibits hypoxia-induced EMT in HNSCC through modulation of HIF-1α, Twist, SNAI2/Slug, TGF-β/Smad signaling, and FAK/actin cytoskeleton rearrangement. The results presented here may provide novel insight into the mechanism of action of microtubule inhibitors for inhibiting EMT. MPT0B098 has great potential for clinical treatment of hypoxic tumors and merits further investigation.
All authors sincerely acknowledge Ms. Hsin-Yi Pan for assisting graphics processing, and thank the funding support.
This study was supported by following grants from the following agencies: the Ministry of Health and Welfare (CA105-SP-01), the National Health Research Institutes (CA-105-PP-22), the Ministry of Science and Technology (MOST 105–2325-B-400-001; MOST-105-2320-B-400-011-MY3), and Ministry of Education (Aim for the Top University Project at National Cheng Kung University) of Taiwan.
Availability of data and materials
JYC and CCK provided the conception and design the study. ITT performed the experiments. ITT and CCK analyzed data. CCK, ITT, and JYC wrote the main manuscript text. JPL Designed and synthesized MPT0B098. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 12.Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang JY. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1alpha mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Cancer Ther. 2013;12(7):1202–12.CrossRefPubMedGoogle Scholar
- 15.Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N, Rocco G. Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One. 2011;6(6):e21548.CrossRefPubMedCentralPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.